Quantcast

Industry news that matters to you.  Learn more

Columbia University Medical Center Sponsors Clinical Study Using Biocept’s Liquid Biopsy Platform to Evaluate Cerebrospinal Fluid of Breast Cancer Patients for Metastatic Biomarkers

Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announces that Columbia University Medical Center will conduct a study to evaluate the clinical utility of the Company’s Target Selector™ platform to diagnose leptomeningeal metastases (LM) in patients with breast cancer.  LM occurs when tumor cells gain access to cerebrospinal fluid (CSF) pathways and regrow in distant sites within the spinal cord and brain leading to neurological complications. Biocept’s liquid biopsy platform will be used to test the CSF of breast cancer patients and will be compared to standard methods for confirming the diagnosis of LM.

Menarini-Silicon Biosystems to Acquire CELLSEARCH CTC System

Menarini-Silicon Biosystems today announced they have signed an agreement to purchase all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell (CTC) system from Janssen Diagnostics, LLC. CELLSEARCH® is used to help manage patients with metastatic breast, prostate, and colorectal cancers. It is the only FDA-cleared CTC test, and has also been approved by China’s FDA for use in monitoring breast cancer patients. Financial details were not disclosed.

GenePool from Station X to Help Epic Sciences Analyze Circulating Tumor Cell Data

Station X, Inc., a pioneer in solving big data analytics and platform integration challenges for customers engaging in genomics-based clinical research and medical applications, recently announced that Epic Sciences will use its GenePool® platform to facilitate data interpretation and collaboration with biopharmaceutical companies developing companion diagnostics based on the company’s innovative circulating tumor cell (CTC) technology.

Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient’s blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

NUS Scientists a Step Closer to Developing Blood Test to Monitor Status of Cancer and Treatment Outcome

Scientists from the National University of Singapore (NUS) have developed a novel technique to efficiently culture clusters containing circulating tumour cells (CTCs) in 14 days that could be used to predict the outcome of cancer treatment as well as monitor the status of cancer. Using the technique, the team achieved a success rate of more than 60 per cent in culturing CTCs from patients with metastatic breast cancer, the highest known success record to-date. This breakthrough brings researchers a step closer towards enabling personalised cancer treatment and monitoring.